AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22922768 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid and/or immunosuppressive therapy (control group)
Number of subjects: 40
Study 20519806 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (M)
Number of subjects: 0
Study 20519806 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (S)
Number of subjects: 0
Study 20519806 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol and Sitagliptin (M+S)
Number of subjects: 0
Study 20519806 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study 18230824 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 93
Study 18230824 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy diet (VLED, 800 kcal/day)
Number of subjects: 93
Study 18230824 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (3 years)
Number of subjects: 93
Study 18230824 — intervention group
Group type: COMPARATOR
Intervention: Combined analysis of both groups
Number of subjects: 93
Study 18230824 — intervention group
Group type: COMPARATOR
Intervention: Weight loss (short- and long-term)
Number of subjects: 93
Study 16394405 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation C (mometasone furoate)
Number of subjects: 0
Study 16394405 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A (mometasone furoate)
Number of subjects: 0
Study 16394405 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation D (mometasone furoate)
Number of subjects: 0
Study 16394405 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 16394405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not specified)
Number of subjects: 0
Study 15590180 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine with doxifluridine
Number of subjects: 48
Study 15590180 — intervention group
Group type: COMPARATOR
Intervention: paclitaxel with doxifluridine
Number of subjects: 48
Study 10767241 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliances with 2-mm mandibular advancement
Number of subjects: 37
Study 10767241 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliances with 4-mm mandibular advancement
Number of subjects: 37
Study 10767241 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliances with 6-mm mandibular advancement
Number of subjects: 37
Study 10767241 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral appliances (all advancements)
Number of subjects: 37
Study 9130733 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a plus EE-CPA pill
Number of subjects: 24
Study 9130733 — intervention group
Group type: COMPARATOR
Intervention: EE-CPA pill alone
Number of subjects: 24
Study 8452318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide as dry powder (400 micrograms daily, one inhalation/nostril/day)
Number of subjects: 60
Study 8452318 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide as aerosol (400 micrograms daily, two puffs/nostril/day)
Number of subjects: 60
Study 8452318 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable, both groups received active treatment)
Number of subjects: 60
Study 3021501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg q.i.d.
Number of subjects: 0
Study 3021501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29682715 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing sutures
Number of subjects: 291
Study 29682715 — intervention group
Group type: COMPARATOR
Intervention: Control (no reinforcing sutures)
Number of subjects: 291
Study 29682715 — intervention group
Group type: COMPARATOR
Intervention: Control (high-risk group)
Number of subjects: 291
Study 29682715 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing sutures (high-risk group)
Number of subjects: 291
Study 29682715 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing sutures (low-risk group)
Number of subjects: 291
Study 29682715 — intervention group
Group type: COMPARATOR
Intervention: Control (low-risk group)
Number of subjects: 291
Study 26795282 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz, maraviroc or maraviroc+raltegravir with fixed-dose tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 32
Study 26795282 — intervention group
Group type: EXPERIMENTAL
Intervention: maraviroc
Number of subjects: 32
Study 26795282 — intervention group
Group type: COMPARATOR
Intervention: Control group (HIV- controls)
Number of subjects: 32
Study 24532547 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg once daily for 8 days)
Number of subjects: 16
Study 24532547 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 8 days)
Number of subjects: 16
Study 23520776 — intervention group
Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy
Number of subjects: 20
Study 23520776 — intervention group
Group type: COMPARATOR
Intervention: Control group (simple mandibular fractures)
Number of subjects: 20
Study 20546629 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of Care Testing (PoCT) for ACR
Number of subjects: 4968
Study 20546629 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of Care Testing (PoCT) for INR
Number of subjects: 4968
Study 20546629 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of Care Testing (PoCT) for HbA1c
Number of subjects: 4968
Study 20546629 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of Care Testing (PoCT) for Lipids
Number of subjects: 4968
Study 20546629 — intervention group
Group type: COMPARATOR
Intervention: Usual testing practice through a pathology laboratory
Number of subjects: 4968
Study 18800217 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief image-based multiple-behavior intervention (MBI)
Number of subjects: 303
Study 18800217 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 303
Study 16158375 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking at 2.7 km/h, 3.6 km/h, and 4.5 km/h (speed variation)
Number of subjects: 47
Study 14521272 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning impaired (LI) children
Number of subjects: 240
Study 14521272 — intervention group
Group type: COMPARATOR
Intervention: Non-learning impaired (NLI) children
Number of subjects: 240
Study 14521272 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-motor correlation
Number of subjects: 240
Study 14521272 — intervention group
Group type: COMPARATOR
Intervention: Visual-motor correlations in NLI group
Number of subjects: 240
Study 10463000 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep method
Number of subjects: 972
Study 10463000 — intervention group
Group type: COMPARATOR
Intervention: Conventional Papanicolaou smears
Number of subjects: 972
Study 8526786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate hemofiltration (HF)
Number of subjects: 6
Study 8526786 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate hemofiltration (HF)
Number of subjects: 6
Study 2371077 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate (n = 10, mean age 21 weeks)
Number of subjects: 27
Study 2371077 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized saline (n = 10, mean age 19 weeks)
Number of subjects: 27
Study 2371077 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (n = 7, mean age 22 weeks)
Number of subjects: 27
Study 278459 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.0075 mg/kg
Number of subjects: 100
Study 278459 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg
Number of subjects: 100
Study 278459 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.02 mg/kg
Number of subjects: 100
Study 278459 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg to 0.02 mg/kg
Number of subjects: 100
Study 278459 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (various dosages)
Number of subjects: 100
Study 29938420 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular 17‐alpha hydroxyprogesterone
Number of subjects: 132
Study 29938420 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular Neurobion
Number of subjects: 132
Study 26795937 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based training with CBT supervision via Skype (IBT-S)
Number of subjects: 61
Study 26795937 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based training with use of a consultation worksheet (IBT-CW)
Number of subjects: 61
Study 26795937 — intervention group
Group type: COMPARATOR
Intervention: Delayed-training controls (DTs)
Number of subjects: 61
Study 24068472 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO group
Number of subjects: 146
Study 24068472 — intervention group
Group type: COMPARATOR
Intervention: Clinical group
Number of subjects: 146
Study 22717414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer lactate solution at 240 mL per hour (group 4)
Number of subjects: 120
Study 22717414 — intervention group
Group type: COMPARATOR
Intervention: No intravenous hydration (group 1)
Number of subjects: 120
Study 22717414 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer lactate solution (any group)
Number of subjects: 120
Study 20393152 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated fasting glucose levels in nondiabetic individuals
Number of subjects: 8447
Study 20393152 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance (homeostasis model assessment index)
Number of subjects: 8447
Study 20393152 — intervention group
Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 8447
Study 18499399 — intervention group
Group type: EXPERIMENTAL
Intervention: ferrous sulfate (200 mg twice a day, corresponding to 80 mg of elemental iron)
Number of subjects: 18
Study 18499399 — intervention group
Group type: COMPARATOR
Intervention: ferrous glycinate chelate (250 mg/d, corresponding to 50 mg of elemental iron)
Number of subjects: 18
Study 15925562 — intervention group
Group type: EXPERIMENTAL
Intervention: Celacade (immune modulation therapy)
Number of subjects: 75
Study 15925562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 14728394 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes management tool developed for a Personal Digital Assistant (PDA)
Number of subjects: 0
Study 14728394 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10515014 — intervention group
Group type: EXPERIMENTAL
Intervention: Milwaukee brace
Number of subjects: 102
Study 10515014 — intervention group
Group type: COMPARATOR
Intervention: Boston brace
Number of subjects: 102
Study 10515014 — intervention group
Group type: COMPARATOR
Intervention: TLSO
Number of subjects: 102
Study 10515014 — intervention group
Group type: COMPARATOR
Intervention: Charleston bending orthosis
Number of subjects: 102
Study 7733032 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of vitamin A
Number of subjects: 295
Study 7733032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 2178916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 0
Study 7433340 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 17
Study 6441523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas vaccine
Number of subjects: 34
Study 6441523 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 30393950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 743
Study 30393950 — intervention group
Group type: COMPARATOR
Intervention: Placebo (discontinuing sitagliptin)
Number of subjects: 743
Study 30297834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium‐Butyrate (SB) added to milk replacer
Number of subjects: 16
Study 25604346 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain (1000 mg·day(‐1))
Number of subjects: 15
Study 24571917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 9
Study 24571917 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recovery (AR)
Number of subjects: 9
Study 24571917 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive rest (PR)
Number of subjects: 9
Study 22744992 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii-fit
Number of subjects: 0
Study 22744992 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated exercise
Number of subjects: 0
Study 22744992 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 20089725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of total protein
Number of subjects: 159
Study 20089725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of lactose
Number of subjects: 159
Study 20089725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of calcium
Number of subjects: 159
Study 20089725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of sodium
Number of subjects: 159
Study 20089725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of total fat
Number of subjects: 159
Study 20089725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of dietary fiber
Number of subjects: 159
Study 20089725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of vegetable protein
Number of subjects: 159
Study 20089725 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index-for-age percentile
Number of subjects: 159
Study 17352404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP), 4 capsules of 28 mg (total 112 mg)
Number of subjects: 90
Study 17352404 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin solution for inhalation (TSI), 300 mg
Number of subjects: 90
Study 17352404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP)
Number of subjects: 90
Study 16286669 — intervention group
Group type: EXPERIMENTAL
Intervention: EVA (560 mg/d)
Number of subjects: 46
Study 16286669 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 46
Study 11856066 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with VLBW and high gestational age
Number of subjects: 44
Study 11856066 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with VLBW and low gestational age
Number of subjects: 44
Study 11856066 — intervention group
Group type: COMPARATOR
Intervention: Full-term infants
Number of subjects: 44
Study 10325894 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic training (group 1, n = 26)
Number of subjects: 42
Study 10325894 — intervention group
Group type: COMPARATOR
Intervention: Untrained group (group 2, n = 16)
Number of subjects: 42
Study 7622632 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene and scaling
Number of subjects: 64
Study 7622632 — intervention group
Group type: EXPERIMENTAL
Intervention: Full initial therapy including root planning
Number of subjects: 64
Study 7622632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 64
Study 2645848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate (0.5 mg/kg/d)
Number of subjects: 20
Study 2645848 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride (0.6 mg/kg/d increased to 2.0 mg/kg/d)
Number of subjects: 20
Study 2645848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2645848 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine sulfate and Fenfluramine hydrochloride
Number of subjects: 20
Study 2645848 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride
Number of subjects: 20
Study 353461 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenoptin (1 tablet 3 times per day for 8 weeks, then reduced to 1 tablet twice per day)
Number of subjects: 20
Study 353461 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet 3 times per day for 8 weeks, then reduced to 1 tablet twice per day)
Number of subjects: 20
Study 31361631 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular block (SCB)
Number of subjects: 103
Study 31361631 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block (ISB)
Number of subjects: 103
Study 28155333 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril 30-60 mg daily
Number of subjects: 3542
Study 28155333 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 5-10 mg daily
Number of subjects: 3542
Study 28155333 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 10 mg daily
Number of subjects: 3542
Study 28155333 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 3542
Study 26168925 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (5 attempts)
Number of subjects: 52
Study 23684280 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium abutments
Number of subjects: 22
Study 23684280 — intervention group
Group type: COMPARATOR
Intervention: Zirconia abutments
Number of subjects: 22
Study 21793387 — intervention group
Group type: EXPERIMENTAL
Intervention: Jin's 'Sanzhen' therapy
Number of subjects: 254
Study 21793387 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation training
Number of subjects: 254
Study 21793387 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Jin's 'Sanzhen' therapy and rehabilitation training
Number of subjects: 254
Study 19141327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg once daily
Number of subjects: 744
Study 19141327 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 88 microg twice daily
Number of subjects: 744
Study 19141327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg once daily
Number of subjects: 744
Study 17162058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 20
Study 17162058 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 20
Study 17162058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15162076 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 15162076 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study 10795118 — intervention group
Group type: EXPERIMENTAL
Intervention: epirubicin 90 mg/m2-paclitaxel 175 mg/m2; 4 cycles bi-weekly, supported by G-CSF 5 micrograms/kg day 5-13 and 3 sequential cycles of CMF 600/40/600 mg/m2 at 2-weeks interval
Number of subjects: 127
Study 10795118 — intervention group
Group type: COMPARATOR
Intervention: epirubicin 90 mg/m2-cyclophosphamide 600 mg/m2; 4 cycles tri-weekly, and 3 sequential cycles of CMF 600/40/600 mg/m2 at 3-weeks interval
Number of subjects: 127
Study 9398893 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin and omeprazole
Number of subjects: 208
Study 9398893 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole and placebo
Number of subjects: 208
Study 1549937 — intervention group
Group type: EXPERIMENTAL
Intervention: oral clonidine 300 micrograms 120 min before surgery
Number of subjects: 100
Study 1549937 — intervention group
Group type: COMPARATOR
Intervention: oral diazepam 0.15 mg/kg 120 min before surgery
Number of subjects: 100
Study 3994920 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 13
Study 3994920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29232560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 1 g administered preoperatively
Number of subjects: 96
Study 29232560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 96
Study 29232560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 1 g administered preoperatively in women
Number of subjects: 96
Study 29232560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) in women
Number of subjects: 96
Study 29232560 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 1 g administered preoperatively in men
Number of subjects: 96
Study 29232560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) in men
Number of subjects: 96
Study 28233454 — intervention group
Group type: EXPERIMENTAL
Intervention: High MUFA (HMUFA) diet
Number of subjects: 75
Study 28233454 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-complex carbohydrate diet supplemented with long-chain n-3 PUFA
Number of subjects: 75
Study 28233454 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-complex carbohydrate diet (placebo)
Number of subjects: 75
Study 28233454 — intervention group
Group type: COMPARATOR
Intervention: High SFA (HSFA) diet
Number of subjects: 75
Study 26123177 — intervention group
Group type: EXPERIMENTAL
Intervention: Efron's biased coin design with varying bias p (0.5 to 1)
Number of subjects: 0
Study 26123177 — intervention group
Group type: COMPARATOR
Intervention: Efron's biased coin design
Number of subjects: 0
Study 24293753 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 14
Study 24293753 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 14
Study 21196081 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse treatment initiation and engagement
Number of subjects: 0
Study 21196081 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance abuse treatment engagement
Number of subjects: 0
Study 18958548 — intervention group
Group type: EXPERIMENTAL
Intervention: Group H (prednisolone > or =10,000 mg)
Number of subjects: 30
Study 18958548 — intervention group
Group type: COMPARATOR
Intervention: Group L (prednisolone <10,000 mg)
Number of subjects: 30
Study 18958548 — intervention group
Group type: COMPARATOR
Intervention: Controls (healthy subjects)
Number of subjects: 30
Study 17000365 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue synchronization imaging (TSI)
Number of subjects: 100
Study 17000365 — intervention group
Group type: COMPARATOR
Intervention: Prolonged QRS duration (> 120 ms)
Number of subjects: 100
Study 17000365 — intervention group
Group type: COMPARATOR
Intervention: Narrow QRS duration (< 120 ms)
Number of subjects: 100
Study 17000365 — intervention group
Group type: COMPARATOR
Intervention: QRS criteria alone
Number of subjects: 100
Study 12947997 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy
Number of subjects: 0
Study 12947997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal immunotherapy
Number of subjects: 0